Therapies Trying to Fight Against Cancer
FinancialBuzz.com News Commentary
NEW YORK, March 25, 2019 /PRNewswire/ -- Over the past two decades, U.S. cancer-related deaths have significantly declined. As of 2015, the death rate for both men and women declined by 26% from its peak in 1991, according to the American Cancer Society. Additionally, the decline in cancer mortality is particularly attributable to the advancements within the cancer biotechnology industry. Certain players within the industry have developed more efficient and effective forms of treatment for patients in order to suppress or ultimately eradicate their cancers. Other biotech players have also manufactured early detectors for cancer in order to find signs before cancer even develops. Lung cancer, which is one of the leaders in cancer-related deaths, saw related deaths decrease by 45% from 1990 to 2015. Similarly, deaths associated with breast cancer, prostate cancer, and colorectal cancer all declined drastically in the past two decades. Despite the dwindling number of deaths, the number of cancer-related cases still continues to grow, as the National Cancer Institute suggested that in 2018 there would approximately 1.73 million new cancer-related cases and projected that 609,640 will die from the disease within the U.S. According to data compiled by Allied Market Research, the global oncology and cancer drugs market was valued at USD 97.40 Billion in 2017 and is expected to reach USD 176.51 Billion by 2025. Additionally, the market is also projected to grow at a CAGR of 7.6% from 2018 to 2025. SourcingLink.net, Inc. (OTC: SNET), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Agenus Inc. (NASDAQ: AGEN), CEL-SCI Corporation (NYSE: CVM), Aptose Biosciences Inc. (NASDAQ: APTO) (TSX: APS)
With the advancement of the cancer therapy market, new forms of treatment are now being studied and manufactured. Chemotherapy remains one of the most common treatments for cancer, however, with the expansion of the market, new therapies such as personalized medicine, immunotherapy, CAR T-cell therapy, radiation therapy, and targeted therapies have become highly popular in their own right. In particular, the targeted therapies market is one of the fastest growing. Targeted therapies are drugs that block the growth and spread of cancer by interfering with specific molecules involved in the growth, progression, and spread of cancerous cells, according to the National Cancer Institute. Targeted therapies differ from chemotherapy as they act upon specific molecules and deliberately choose their target. On the other hand, chemotherapy normally attacks and kill rapidly dividing cancerous cells. Targeted therapies can aid patients by detecting cancer early on, as well as helping the patient through treatment. "Everything today is becoming more and more personalized. With cancer treatments, the genomic information on the tumor is increasingly becoming available as the cost of sequencing continues to drop. We can expect a future where we will have much more precise treatments based upon the genomic signature of the patient," said Sean Marett, Chief Brand Officer and Chief Commercial Officer of German immuno-oncology company BioNTech. "A pharmacy will no longer be selling tablets off the shelf. We're going to be delivering a specific treatment only for the patient."
SourcingLink.net, Inc. (OTC: SNET) just announced breaking news this morning that, "it entered into an exclusive worldwide licensing agreement with NanoSmart Pharmaceuticals, Inc. for the right to use NanoSmart's nanoparticle platform technologies to develop and commercialize improved formulations of doxorubicin for the treatment of human cancers. The license includes access to one of NanoSmart's lead drug formulations, ANA- Conjugated Liposomal Doxorubicin, which has been previously granted Orphan Drug Designation by the US Food and Drug Administration. Under the terms of the agreement, NanoSmart will receive an upfront fee, restricted common shares of SNET stock, an annual maintenance fee, and a high single-digit royalty on net sales of formulations that incorporate NanoSmart's intellectual property.
SourcingLink.net stated, "We are pleased to have licensed the application of NanoSmart's tumor-targeting technology to improve doxorubicin formulations. This is a significant extension of our oncology product portfolio to address the growing need for improved cancer therapies. We look forward to initiating nonclinical development, clinical trials, FDA submission, and commercialization of a tumor-targeting drug product and to explore combination with our proprietary liquid biopsy platform to potentially deliver personalized treatment paradigms that are safer and more effective than existing options."
Doxorubicin is a well-established anthracycline chemotherapeutic drug used for treating a broad range of cancers such as ovarian, breast, bladder, Kaposi's sarcoma, lymphomas, thyroid, neuroblastoma and lung cancers. Commercializing a targeted doxorubicin formulation provides the opportunity to impact millions of cancer patients worldwide and to provide better therapy options for the growing global cancer population, including rare cancers with unmet needs. Dr. James Smith, President and CEO of NanoSmart Pharmaceuticals, stated, "Our initial non-clinical testing on ANA-conjugated liposomal doxorubicin is very promising, and we believe that SNET's involvement will enable the efficient commercialization of one of our lead candidate formulations and further validate the performance of our proprietary drug delivery platform technologies."
About SourcingLink.net - SourcingLink.net, Inc. ("SNET") is a pioneering oncology company dedicated to developing, manufacturing and commercialization of therapeutics. SNET licensed Tulynode's patent pending Autologous Immuno-therapy for durable therapy response using an extracorporeal device. SourcingLink.net prides itself for having a world-class Advisory Board that keeps the Company leadership in the forefront of developing technologies in cancer research, biotechnology and healthcare. SourcingLink.net is currently engaging in research and development of therapeutics for oncology. SourcingLink.net is committed to its core corporate mission and values of highest U.S. Pharma Code of Conduct standards of behavior for being in compliance with the laws, regulations, company directives and guidance.